The newly identified strain of the virus contains multiple spike protein mutations, as well as mutations in other areas of the viral genome, and may increase SARS-CoV-2 transmissibility by up to 70%.

Twist said it expects the new control to be available by January 15, 2021.

Twist offers new gene fragments to the synthetic biology market
Twist Bioscience has launched its new clonal-ready gene fragments. The gene fragments, with and without adapters, can be used to rapidly build constructs...

Twist Bioscience touts positive preclinical data for SARS-CoV-2 antibodies
Twist Bioscience has touted preclinical results for three of its proprietary antibodies against the novel coronavirus S1 subunit protein.

Firms partner with Microsoft to advance DNA data storage
Twist Bioscience, Illumina, and Western Digital have formed an alliance with Microsoft to advance the field of DNA data storage.

ImmunoPrecise, Twist collaborate on novel therapeutics
ImmunoPrecise subsidiary Talem Therapeutics and Twist Bioscience will collaborate on the creation of novel therapeutic molecules.

Twist Bioscience finds new SARS-CoV-2 neutralizers
Twist Bioscience has identified immunoglobulin G antibodies and single dose domain VHH nanobodies that have neutralizing effects against SARS-CoV-2.